BioMarin Pharmaceutical (NASDAQ:BMRN) Issues FY 2026 Earnings Guidance

BioMarin Pharmaceutical (NASDAQ:BMRN) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 4.900-5.100 for the period, compared to the consensus estimate of 4.800. The company issued revenue guidance of $3.9 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion.

BioMarin Pharmaceutical Stock Up 2.6%

Shares of BMRN stock opened at $61.46 on Friday. BioMarin Pharmaceutical has a 12-month low of $49.26 and a 12-month high of $66.28. The company has a quick ratio of 4.20, a current ratio of 5.81 and a debt-to-equity ratio of 0.23. The firm has a fifty day moving average of $58.06 and a 200-day moving average of $57.01. The company has a market capitalization of $11.88 billion, a price-to-earnings ratio of 44.86, a P/E/G ratio of 0.46 and a beta of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.25. The firm had revenue of $989.71 million during the quarter, compared to analysts’ expectations of $932.03 million. BioMarin Pharmaceutical had a return on equity of 6.50% and a net margin of 8.29%.The company’s revenue was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. As a group, equities research analysts predict that BioMarin Pharmaceutical will post 4.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Bank of America cut their price objective on shares of BioMarin Pharmaceutical from $85.00 to $80.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Citigroup upped their target price on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Weiss Ratings raised BioMarin Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, June 26th. Royal Bank Of Canada cut their price objective on BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating for the company in a report on Tuesday, July 7th. Finally, Sanford C. Bernstein lowered their target price on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating on the stock in a report on Tuesday, May 5th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $87.09.

Trending Headlines about BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin reported second-quarter adjusted earnings of $1.20 per share, exceeding the $0.95–$0.96 analyst consensus. Revenue rose 20% year over year to approximately $990 million, well above expectations of roughly $932 million. BioMarin Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: The company raised its full-year 2026 adjusted diluted EPS guidance to $4.90–$5.10, above the prior analyst consensus of about $4.80. Management also cited stronger growth expectations for total revenue and VOXZOGO. BioMarin Pharmaceutical Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management said the addition of GALAFOLD and POMBILITI plus OPFOLDA, together with expected cost synergies, should accelerate revenue growth, improve EPS, expand operating margins and increase operating cash flow through the mid-2030s. BioMarin Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the earnings beat, quarterly EPS declined from $1.44 in the year-earlier period to $1.20, which may temper enthusiasm about near-term profitability. Full-year revenue guidance of approximately $3.9 billion was broadly in line with consensus rather than a major upside surprise. Compared to Estimates, BioMarin Q2 Earnings: A Look at Key Metrics

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of BMRN. CIBC Private Wealth Group LLC boosted its holdings in shares of BioMarin Pharmaceutical by 38.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 179 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in BioMarin Pharmaceutical during the 3rd quarter worth about $40,000. Parallel Advisors LLC boosted its position in shares of BioMarin Pharmaceutical by 62.2% during the 3rd quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 295 shares in the last quarter. Meeder Asset Management Inc. increased its holdings in BioMarin Pharmaceutical by 1,974.1% in the fourth quarter. Meeder Asset Management Inc. now owns 1,763 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 1,678 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new position in shares of BioMarin Pharmaceutical during the 4th quarter worth approximately $201,000. Institutional investors and hedge funds own 98.71% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.